Please login to the form below

irritable bowel syndrome

This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.

verdict on the use of the drug in irritable bowel syndrome.

China approves Ironwood Pharma’s IBS treatment

Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Approval by China’s NMPA for adults with irritable
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

pain associated with irritable bowel syndrome (IBSs).
NHS could save £7bn with greater diagnostics use

The report specifically evaluated the savings of three existing IVD tests - covering suspected heart attacks, pre-eclampsia in pregnancy and diagnosing irritable bowel syndrome (IBS) - if widely used. ... Lastly, IVDs for common bowel condition IBS could
Mallinckrodt pays $1.2bn for Sucampo Pharma

Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid
NICE backs Allergan's IBS therapy Truberzi

NICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.

More from news
Approximately 0 fully matching, plus 49 partially matching documents found.

Erectile dysfunction, constipation, vaginal dryness and other laughing matters

An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift
Taking a lean and careful approach

His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
Can biosimilars live up to the hype?

She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of
Oral biologics delivery still elusive

years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which
Pharma deals during April 2014

proteinuria associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. Whilst this is a 60-year old drug acquired by Questcor in 2001 for $100, 000, generic competition is ... delta opioid receptor antagonist for

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Ironwood appoints Edward Owens to board

irritable bowel syndrome and constipation.
Ironwood promotes Dr Mark Currie

Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Diagnosing MS: are we getting it right?

MS symptoms can be hard to pin down. I’ve heard bladder issues being attributed to “women’s problems”, bowel issues to irritable bowel syndrome (IBS), and fatigue to stress and
World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

Symptoms of ovarian cancer. The symptoms of ovarian cancer are quite similar to those for less serious conditions such as irritable bowel syndrome or pre-menstrual syndrome [3]. ... Other symptoms include persistent indigestion or nausea, a change in
Irritable Bowel Syndrome (IBS) patient insights

Irritable Bowel Syndrome: Patient–Provider Interaction and Patient Education. J Clin Med. 2018; 7(1):3. -----. ... Irritable bowel syndrome in adults: diagnosis and management. NICE Clinical Guideline 61; 2017.
IGNIFI

Irritable Bowel Syndrome (IBS) patient insights.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Add my company

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...